NASDAQ · XAIR

Beyond Air, Inc.

$5.16 -$0.31 (-5.67%) 1D Market open

Key Metrics

$3.94M
Market cap
P/E · TTM
$7.68M
Revenue · TTM
−$33.25M
Net income
EPS · TTM $-9.82
Dividend yield
Free cash flow −$19.17M
Beta · 1Y 0.56
EBITDA · TTM −$31.29M
Gross margin 3.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 29 high, the share price fell 79%.

    Peak close $24.60 on Jan 29; trough close $5.16 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -79%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 14
    The stock moved -23.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 14
  • Apr 17
    The stock moved +22.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 17

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.94M
Enterprise value
Shares outstanding720.5K
52-wk range$0.67 – $53.20
Avg volume · 20D199.1K
Net cash
Book value / share$1.81
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Beyond Air, Inc.
IPO dateApr 27, 2016
Employees54

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.51
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 3.3%
Operating -447.1%
Net -433.0%
FCF -249.6%
ROE / ROIC -337.4% · —

Financial Health

Current ratio3.80
Quick ratio3.59
Debt / equity
Debt / EBITDA
Net cash
Working capital$18.26M

Cash Flow · TTM

Operating CF −$18.14M
Capex −$1.03M
Free cash flow −$19.17M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

-14.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings